Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000294657 is a long noncoding RNA annotated as "novel transcript, antisense to CARMIL1," meaning it is transcribed from the opposite strand of the CARMIL1 gene locus. As an antisense lncRNA, it may regulate the expression of the CARMIL1 gene through mechanisms such as transcript interference, chromatin modification, or effects on mRNA stability and translation, as described for other antisense lncRNAs[5]. There is currently no evidence that this lncRNA encodes a protein or acts as a therapeutic target, and its precise biological roles are not yet characterized in the literature. Its function may be inferred from the broader class of antisense lncRNAs, which are known to influence gene expression and are increasingly investigated in cancer and gene regulation contexts[3][5].
None reported; general mechanism for antisense lncRNAs includes regulation of neighboring gene expression through RNA-RNA interactions or modulation of transcription/translation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CARMIL1 (ENSG00000294657).